Author Archives: admin


Supernus Provides Regulatory Updates for SPN-812 and SPN-830

ROCKVILLE, Md., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced regulatory updates for SPN-812 (viloxazine hydrochloride) for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age, and SPN-830 (apomorphine infusion pump) for the continuous treatment of motor fluctuations (“on-off” episodes) in Parkinson’s disease (PD).

Read more from the original source:
Supernus Provides Regulatory Updates for SPN-812 and SPN-830

Praxis Precision Medicines Provides Regulatory Update On PRAX-114 Program

CAMBRIDGE, Mass., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system disorders characterized by neuronal imbalance, today announced that it has received a response from the U.S. Food and Drug Administration (FDA) on the Investigational New Drug (IND) submission for PRAX-114 for the treatment of major depressive disorder (MDD).

Excerpt from:
Praxis Precision Medicines Provides Regulatory Update On PRAX-114 Program

Minaris invests to triple capacity in Europe – Bioprocess Insider – BioProcess Insider

The cell and gene therapy CDMO will build additional facilities at its German and Japanese locations.

The contract development and manufacturing organization (CDMO) specializing in cell and gene therapies announced two separate investments of $40.7 million (34.2 million) into its Ottobrunn, Germany, site, and $23.8 million for its Yokohama, Japan, site.

Both regions now come under the umbrella of Minaris Regenerative Medicine, a subsidiary of Showa Denko Materials, after a rebrand in September to unify the name of its three businesses located in North America (previously, Hitachi Chemical Advanced Therapeutics Solutions (HCATS)), Europe (apceth Biopharma), and Japan (Hitachi Chemical).

Image: iStock/oatawa

The Japanese company acquired apceth last year for $86 million and will now add a 6,650-square-meter facility to the German site. The space will include additional clean rooms, quality control laboratories, warehousing, cryo-storage and office space.

Once operational in 2023, the facility will more than triple the current clean room capacity.

A spokesperson for Minaris explained that the facility will feature a modular design, which allows the company to combine two smaller units into one large ball room and to shift from a grade B to grade C to grade B environment according to our clients needs.

The European site became one of the first CDMOs to manufacture a commercial gene therapy, after agreeing a deal with bluebird bio to manufacture its Zynteglo (autologous CD34+ cells encoding A-T87Q-globin gene) product last year.

While the companys Japanese site will also receive an additional facility, which will cover 4,000-square-meters and is scheduled to start operations in October 2022.

The space will be used specifically for the commercial manufacture of regenerative medicine, particularly cancer immunotherapies and somatic stem cells, doubling the sites existing capacity.

Minaris global presence for a cell and gene specialist is unusual for an industry often concentrated in the US. However, the spokesperson for Minaris outlined that a global position confers an advantage to our clients that are seeking a global manufacturer to produce their product in different regions for example, clients with autologous cell products that need a manufacturing site close to the patients.

Additionally, We have regulatory expertise in Europe, Japan and the US and can leverage the expertise of one region to another, the spokesperson added.

Read the rest here:
Minaris invests to triple capacity in Europe - Bioprocess Insider - BioProcess Insider

Cell Therapy Manufacturing Market: Applications and Regional Insights During the Forecasted Period 2020-2030 – PRnews Leader

Prophecy Market Insights added a recent Cell Therapy Manufacturing market report with Revenue, Key Developments, Top Countries Data, SWOT Analysis, COVID-19 impact, Growth and Outlook To 2029 to its research database. The report includes analysis of different factors that drives the market growth. It includes drivers, restrains, opportunities, and trends for the market. Further, the report provides the scope of different segments and applications which can promote the market over the forecast period. The in-depth information is based on historic milestones and current trends.

Get Free Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/21

The report offers detailed information of the growth and other aspects of the Cell Therapy Manufacturing market in different regions, including North America, Europe, Asia pacific, and Middle East & Africa. Key regions covered in the report are the U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, Taiwan, Southeast Asia, Mexico, and Brazil, etc.

Australia, New Zealand, Rest of Asia-Pacific

Further, the report also provides the economic, environmental, social, technological, and political status of each region. This section also analyses region-wise revenue and volume for the forecasted period 2019-2029.

Cell Therapy Manufacturing Market by Top Manufacturers:

harmicell, Merck Group, Dickinson and Company, Thermo Fisher, Lonza Group, Miltenyi Biotec GmBH, Takara Bio Group, STEMCELL Technologies, Cellular Dynamics International, Becton, Osiris Therapeutics, Bio-Rad Laboratories, Inc., Anterogen, MEDIPOST, Holostem Terapie Avanazate, Pluristem Therapeutics, Brammer Bio, CELLforCURE, Gene Therapy Catapult EUFETS, MaSTherCell, PharmaCell, Cognate BioServices and WuXi AppTec.

Competitive landscape section of the Cell Therapy Manufacturing report includes top ten manufacturers along with heat map analysis. The comprehensive report provides a significant microscopic look offering product portfolio, key highlights, financial overview, and business strategies.

Key Takeaways of the market report:

Key Topics Covered:

Important Questions Answered in Cell Therapy Manufacturing Market Report:

Segmentation Overview:

Download PDF Brochure for report overview @ https://www.prophecymarketinsights.com/market_insight/Insight/request-pdf/21

Reasons to purchase the XYX market:

Provides recent collaborations, mergers, acquisitions, and partnerships along with regulatory framework across vast regions impacting the market trajectory

Report Scope

Europe

Asia Pacific

Latin America

Middle East & Africa

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

See the original post:
Cell Therapy Manufacturing Market: Applications and Regional Insights During the Forecasted Period 2020-2030 - PRnews Leader

Human Embryonic Stem Cells (HESC) Market 2020 Manufacturer Analysis, Emerging Trends, Top Companies and Forecast to 2027 – TechnoWeekly

Human Embryonic Stem Cells (HESC) Market Size And Forecast

A comprehensive overview of the Human Embryonic Stem Cells (HESC) Market is recently added by Market Research Intellect to its humongous database. Furthermore, the Human Embryonic Stem Cells (HESC) Market report has been aggregated by collecting informative data of various dynamics such as market drivers, restraints, and opportunities. Furthermore, this innovative report makes use of SWOT, PESTLE, and Porters Five Forces analyses to get a closer outlook on the Human Embryonic Stem Cells (HESC) Market. Furthermore, the Human Embryonic Stem Cells (HESC) Market report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing the market growth. Furthermore, this statistical market research repository examines and estimates the Human Embryonic Stem Cells (HESC) Market at the global and regional levels. The study covers the impact of various drivers and manacles on the Human Embryonic Stem Cells (HESC) Market growth opportunities over the forecast period.

Impact of Covid-19 :

During the first quarter of 2020, different global economies were badly impacted by a viral outbreak of COVID-19. This viral outbreak of the Covid-19 was later recognized as a global pandemic by the World Health Organization (WHO). COVID-19 spread in different global countries, affecting a large number of people in a short timeframe. The outburst of COVID-19 adversely hit different global economies in the world. The stringent regulations imposed by several governments, including complete lockdown and quarantine methodologies to fight against COVID-19, resulted in a massive impact on various business sectors. We at Market Research Intellect offer an informative report on the Human Embryonic Stem Cells (HESC) Market which helps in making strategic decisions over the forecast period.

Competitive Landscape:

The degree of competition among leading global companies has been elaborated by examining various leading key players operating across the global regions An expert team of research analysts sheds light on various attributes such as -global market competition, market share, latest industry developments, innovative product launches, partnerships, mergers or acquisitions by leading companies in the Human Embryonic Stem Cells (HESC) Market. The leading manufacturers have been analyzed by using research methodologies for getting insight views on global competition.

Following key players have been profiled with the help of proven research methodologies:

The Human Embryonic Stem Cells (HESC) Market has been examined into different global market segments such as type, applications and global geographies. Each and every global market segment has been studied to get informative insights into various global regions.

Human Embryonic Stem Cells (HESC) Market Segmentation:

Human Embryonic Stem Cells (HESC) Market Segment by Type:

Human Embryonic Stem Cells (HESC) Market Segment by Application:

Human Embryonic Stem Cells (HESC) Market Segment by Global Presence:

North America Latin America Middle East Asia-Pacific Africa Europe

The report has been aggregated by using a couple of research methodologies such as primary and secondary research techniques. It helps in collecting informative pieces of professional information for deriving effective insights into the market. This informative report helps in making well informed and strategic decisions throughout the forecast period.

Key questions answered through this analytical market research report include:

What are the latest trends, new patterns and technological advancements in the Human Embryonic Stem Cells (HESC) Market? Which factors are influencing the Human Embryonic Stem Cells (HESC) Market over the forecast period? What are the global challenges, threats and risks in the Human Embryonic Stem Cells (HESC) Market? Which factors are propelling and restraining the Human Embryonic Stem Cells (HESC) Market? What are the demanding global regions of the Human Embryonic Stem Cells (HESC) Market? What will be the global market size over the coming future? What are the different effective business strategies followed by global companies?

If you have any custom requirements, please let us know and we will offer you the customized report as per your requirements.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Website https://www.marketresearchintellect.com/

Read more:
Human Embryonic Stem Cells (HESC) Market 2020 Manufacturer Analysis, Emerging Trends, Top Companies and Forecast to 2027 - TechnoWeekly

Voters asked to approve $5.5 billion for stem cell research – Lebanon Express

We built something good, but I think the field has expanded and there's plenty of money going into research in California now, said Jeff Sheehy, who sits on the governing board of the California Institute for Regenerative Medicine but says the state can't afford to borrow more bond money to support it.

When voters approved the initial $3 billion in 2004, President George W. Bush's administration had banned the use of federal funds for research using newly created human embryonic stem cell lines. The Obama administration lifted that ban in 2009.

Since then, opponents say, the National Institutes of Health has provided $1.5 billion a year in stem cell research money, while private investment in companies doing stem cell research has flowed in.

Supporters say that federal money could stop at any time, noting more than 90 members of Congress recently signed a letter demanding the Trump administration put an end to funding stem cell research.

More than a third of the initial $3 billion was spent to create stem cell research facilities at Stanford, the University of California, Berkeley, and other prestigious California institutions. Much of the rest has gone toward research.

With only about $30 million left, the California Institute for Regenerative Medicine has reduced its staff and stopped funding new studies.

If the proposition keeps its lead and passes, at least $1.5 billion would be earmarked for developing treatments for Alzheimer's, Parkinson's and other brain-related diseases. Some funds would be used to train California university and college students, and no more 7.5% could be used for administrative costs.

Go here to read the rest:
Voters asked to approve $5.5 billion for stem cell research - Lebanon Express

Cell Therapy Manufacturing Market to be Worth USD 8 billion by 2030, predicts Roots Analysis – PRnews Leader

Roots Analysis has announced the addition of Cell Therapy Manufacturing Market (2nd Edition), 2018-2030 report to its list of offerings.

Natasha Thakur, the principal analyst, stated, The growing number of cell therapy candidates continues to create an increasing demand for facilities that offer manufacturing services for these complex pharmacological interventions. Presently, over 145 companies / organizations are actively offering manufacturing services for such products. The installed global manufacturing capacity is estimated to be over 1 billion sq ft, with the maximum capacity available in North America

The report presents opinions on several key aspects of the market. Among other elements, it includes:

The report features inputs from a number of eminent industry stakeholders. Thakur remarked, Most of the experts we spoke to confirmed that the manufacturing of cell therapies is largely being outsourced due to exorbitant costs associated with setting-up such facilities. The report features detailed transcripts of discussions held with the following experts:

The research also includes detailed profiles of the following players:

For additional details, please visithttps://www.rootsanalysis.com/reports/view_document/cell-therapy-manufacturing-market-2nd-edition-2018-2030/209.hl or email [emailprotected]

Contact:

Gaurav Chaudhary

+1-604-595-4954

Read the rest here:
Cell Therapy Manufacturing Market to be Worth USD 8 billion by 2030, predicts Roots Analysis - PRnews Leader

Transcriptional priming as a conserved mechanism of lineage diversification in the developing mouse and human neocortex – Science Advances

INTRODUCTION

The cerebral cortex is the seat of higher-order cognition, motor control, and social behavior. It emerges early during embryonic development from a simple epithelial sheet in the prosencephalon and expands into a complex six-layered amalgam of neural cells and circuits, with cell identity, morphology, and function consolidated both by laminar position and regional localization. At least 55 excitatory and 60 inhibitory transcriptomically defined neuron cell types (ExN and InN, respectively) have recently been reported in two regions of the adult mouse neocortex (1), and it is probable that even more cell types exist in other cortical areas and in other mammalian species. This repertoire of neurons is produced during neurogenesis from germinal zone stem and progenitor cells and is essential for the normal development of cognitive, sensory, and motor functions. Alterations in neurogenesis are known to lead to numerous neurodevelopmental and neuropsychiatric disorders (2). Crucially, although the importance of neuron diversity in the neocortex is well recognized, the fundamental mechanisms underlying production of this neuronal variety from the comparatively homogeneous stem and progenitor cells is not currently understood.

All excitatory neocortical neurons are born from two broad classes of neural stem and progenitor cells that reside in the dorsal ventricular and subventricular zones during embryonic development. Apical or ventricular radial glial cells (aRGCs or vRGCs) have been identified as the neural stem cells of the neocortex, because they alone exhibit multipotency and the ability to undergo self-renewing asymmetric cell divisions. Daughter cells born from aRGCs are fated to either become neurons (direct neurogenesis) or to generate the second class of precursors, the intermediate progenitor cells (IPCs), which in turn undergo limited rounds of cell division to amplify neuronal output (indirect neurogenesis) (3, 4). In recent years, subgroups of IPCs have been characterized on the basis of marker gene expression, morphology, cell cycle (CC) dynamics, and the location of their mitosis. These include at least three known IPC types: apical IPCs (aIPCs) (58), basal IPCs (bIPCs) (9, 10), and basal or outer radial glial cells (bRGCs or oRGCs) (1113). Despite the identification of these major apical and basal precursor groups, major deficiencies remain in our understanding of these cells and their roles in generating the extensive neuronal variation that arises during brain development. For example, our recent data indicate that different precursor types can contemporaneously produce excitatory neurons with distinct properties (14, 15). Thus, if aRGCs, aIPCs, bIPCs, and bRGCs are each comprised by distinct subtypes of cells, it could provide a mechanism for generating a wide number of neuron types with specific functions and roles in the cortical circuitry.

Using single-cell droplet capture, we conducted a high-throughput gene expression analysis of neocortical cells in mouse and identified many groups of stem and progenitor cells with distinct transcriptional profiles. Comparison of these results to published human single-cell RNA-sequencing (scRNA-seq) datasets not only (2, 1618) revealed remarkable similarities across species but also highlighted an increase in bRGC diversity in human neocortex. We observed multiple cell types with mixed identity transcriptional profiles, that is, coexpression of genes typically thought to define separate types of stem and progenitor cells. In vivo intersectional fate mapping and in situ gene expression experiments revealing the identity of these cells in both mouse and human brain indicate that transcriptional priming in aRGC subgroups is a primary mechanism used to generate progenitor heterogeneity during neurogenesis. Last, state-of-the-art bioinformatics approaches indicate that, as a population, the neural precursor lineages simultaneously produce multiple streams of cortical neurons. These data, describing the shared and divergent features between rodents and primates, provide a new picture of how neural precursor heterogeneity is leveraged to influence cortical size and neuronal diversity in a species-specific manner.

We used the ddSEQ Single-Cell Isolator (Bio-Rad and Illumina) to capture cells from the developing wall of the cerebral neocortex at embryonic day (E) 15.5, when excitatory neurons destined for the upper layers are generated (Fig. 1A). After applying stringent quality control measures, 5777 cells from multiple litters (N = 8) and two technical replicates were subject to downstream analyses (fig. S1A). Principal components analysis (PCA) of highly variable genes (HVGs) and subsequent gene ontology analysis revealed that the first two principal components (PCs) were related to CC/cell division and neuron differentiation (fig. S1B). To minimize the effect of CC on cell type classification, we next regressed out the variance related to CC (fig. S1, C and D). Using the first 33 PCs (fig. S1E), we then performed t-stochastic neighbor embedding (t-SNE) analysis (19) and Louvain-Jaccard clustering. Cells from the two replicates mixed well, indicating negligible technical variation (fig. S1F). The clustering analysis resulted in the identification of 25 clusters of cells with distinct transcriptional profiles. On the basis of the expression of canonical marker genes, two types of dorsal telencephalic mouse radial glial cells (mRGCs), five types of mouse IPCs (mIPCs), eight types of mouse excitatory neurons (mExN), and six types of mouse inhibitory interneurons (mInN) were identified (Fig. 1B). In addition, we also identified one group of ventral radial glial cells (mRGC3; inadvertently included due to microdissection procedures), ventral progenitor cells (VPs), Cajal-Retzius cells (CRs), and cells from the choroid plexus (CPs). In general, these clusters expressed cell type selective markers including Pax6, Hes1, and Sox2 (RGCs); Dlx1 and Sp9 (VPs); Reln (CRs); and Ttr (CPs), as well as layer-specific neuronal markers including Satb2 (layers 2 to 4) and Sox5 and Fezf2 (layers 5 and 6) (Fig. 1, C and D; figs. S1G and S2; and table S1). Further confirming the putative identities of many of these clusters, weighted gene coexpression network analysis (WGCNA) (20) indicated the concerted expression of numerous gene modules likely to play key functional and cell typespecific roles (Fig. 1E and fig. S3). For example, genes in module 1 (M1), such as Nes, Pax6, Gli3, Hes1, Notch1, Notch2, and Fgfr3, have been associated with apical progenitor populations, and the expression of M1 genes was enriched in mRGC1/2/3 and mIPC1/2 (Fig. 1F). In contrast, genes in M8 were enriched in mIPCs and included the canonical IPC marker gene Tbr2/Eomes and several genes, such as Neurog1 and Neurog2, which have been associated with IPCs (Fig. 1F). This module also included Mfng and Mfap4, genes encoding extracellular matrix proteins involved in cell adhesion or intercellular interactions whose role in IPCs has not been extensively characterized. WGCNA also identified core gene expression networks expressed in mExN subtypes (M10, M11, and M12) and in mInN subtypes (M12, M13, and M14). These core gene networks likely play fundamental roles in establishing and maintaining the identity and function of the corresponding cell types.

(A) Schematics of experimental design. Dissociated neocortical cells from embryonic day 15.5 (E15.5) mouse brain were captured by ddSEQ method. (B) t-SNE plot of single cells from E15.5 mouse cortex. Colors represent cell types. VP, ventral progenitor; CR, Cajal-Retzius cell; CP, choroid plexus. (C) Feature plots of canonical marker gene expression. Heatmap represents normalized level of gene expression. The number of cells in each cell type is indicated in parentheses (D) Heatmap of differentially expressed (DEX) genes between cell types. Colors represent cell types as in (B). Two of the DEX genes from each cell type are listed on the right. (E) Weighted gene correlation networks of all mouse cell types found in the current dataset. Seventeen coexpression modules are identified. Size of the dots indicates level of correlation between network and cell type, whereas colors represent level of significance (Bonferroni-corrected P value). (F) Genes in module 1 (M1: RGC) and module 8 (M8: IPC) are shown.

Although the WGCNA and marker gene expression were sufficient to discriminate and provisionally uncover the cellular identity within the dataset, several cell types were found to be simultaneously associated with mixed molecular signatures. For example, both mRGC2 and mIPC1 expressed apical progenitor markers, including Sox2, Hes1, and Fabp7, as well as basal progenitor markers such as Eomes. Although these mixed character cells may represent transitional phases between apical and basal progenitor types, we were struck by the remarkably high proportion of such cells within their corresponding cell types (fig. S4, A to C). Similarly, some clusters were highly correlated for the expression of genes in WGCNA modules, indicative of alternate cell identities. For example, although M8 included several genes known to be associated with mIPCs, mRGC2 was also enriched for the expression of genes in M8 (Fig. 1E). These results raised the possibility that such mixed signatures may be distinct cellular states contributing to differentiation or lineage diversification.

To distinguish whether mixed character progenitors represent transient and transitional or stable and distinctive cell states, we first assessed the diversity of cells within each cluster by intracluster distance (fig. S4D). We found that mRGC cell types generally showed higher transcriptome complexity, demonstrated by a high level of intracluster distance, compared with other cell types; mRGC2, which contained cells exhibiting a mixed RGC/IPC expression profile, was the most diverse. This observation prompted us to investigate the substructure within each progenitor cell type using pseudotime analysis (21), which identified multiple states within mRGC1 and mRGC2. We identified three states in mRGC1 that were related to CC progression (Fig. 2A and fig. S4E), demonstrated by gene expression patterns of CC-related genes along pseudotime (fig. S4F). However, in mRGC2, we found four states that appeared to reflect distinctive lineage commitments, as evidenced by the expression of lineage-selective marker genes (Fig. 2B). In particular, state II in mRGC2 was enriched for Eomes expression as compared with all other states in both mRGC1 and mRGC2 (Fig. 2C). Differential expression (DEX) analysis between the four mRGC2 states confirmed that state II was enriched with bIPC genes, including Eomes and Mfng (fig. S4G). Notably, although mRGC2 state II exhibited higher Eomes expression relative to other mRGCs, its expression of Eomes and other IPC markers was significantly lower than found in mIPC cell types.

(A and B) Pseudotime trajectory of mRGC1 (A) and mRGC2 (B). Color indicates pseudotime progression. Cell states are indicated with circled Roman numerals. Genes showing strong association with pseudotime, and cell states are shown at the bottom of each panel. (C) Boxplot of Eomes expression levels in each cell state (circled Roman numerals) of mRGC cell types. Asterisks indicate statistical significance (Fishers exact test) compared with any other cell state. (D) Eomes-Cre IUE-based fate mapping demonstrates multiple cell morphotypes including aRGCs, bIPCs, and bRGCs. (E) IUE of Eomes-Cre with dual-color StopLight reporter using PH3 to isolate mitotic cells. A subpopulation of Eomes-Creexpressing cells divides at the VZ surface while nonTbr2-Creexpressing cells primarily divide at the VZ surface. (F) Location of PH3+ divisions by Eomes-Cre fate map lineage. (G) Proportion of precursors dividing at the surface of the lateral ventricle or subapically differs by lineage; 36.7% of mitotic cells expressing Eomes-Cre divide at the ventricular surface. Mann-Whitney U test, n = 3, P < 0.001. (H to J) Cells with aRGC morphology expressing Eomes-Cre plasmid do not express EOMES protein. (K and L) Precursors expressing Eomes-Cre plasmid express Eomes mRNA. Scale bars, 20 mm.

To determine whether some aRGCs in the mouse neocortex may express Eomes and to test whether this expression reflects lineage identity, we used in utero electroporation (IUE) to label precursors at E11.5 and E14.5 with plasmids expressing mCherry under the control of the Eomes promoter along with a plasmid expressing Lyngreen fluorescent protein (GFP) from the constitutive EF1 promoter. After classifying precursor types based on morphological properties, these experiments showed that 16% of bipolar apical precursors (presumed aRGCs) and 32% of the unipolar apical precursors express the pEomes construct at E12.5 (fig. S5, A to C). The percentages of bipolar and unipolar apical precursors increased to 35 and 72% at E14.5, respectively (fig. S5, D to F). To also assess this question with fate mapping constructs, we performed IUE with a plasmid expressing membrane-tagged Lyn-GFP governed by Cre recombination driven by the Eomes promoter into the E14.5 developing neocortical wall. Twenty-four hours later, this labeling method elucidated multiple classes of progenitors expressing the Eomes promoter construct, identified by morphological and anatomical properties as aRGCs, aIPCs, bIPCs, and bRGCs (Fig. 2D) (22). To confirm expression of Eomes by aRGCs, we next electroporated E13.5 brains with pEomes-Cre and a conditional dual-color StopLight plasmid that expresses mCherry after Cre-mediated recombination (Fig. 2E), followed 24 hours later by immunohistochemical labeling for phosphorylated histone H3, a marker for mitotic cells. Consistent with the prominence and rapid cycling of aRGCs, the majority of pEomes-Crenegative cells (ZsGreen-positive) were located at apical positions near the ventricle. In contrast, and in agreement with the canonical view of Eomes expression by basal progenitors, most (63.3%) pEomes-Cre (mCherry)expressing cells divided at basal positions away from the ventricle (Fig. 2, F and G). However, we also observed that approximately 36.7% of the cells expressing mCherry following Eomes-Cremediated recombination were found dividing at the ventricular zone (VZ) surface, the preferential location for aRGC mitoses, most likely representing cells of the mRGC2 cluster. To confirm that the pEomes-Cre plasmid faithfully reports endogenous Eomes expression, we used single molecular fluorescent RNA in situ hybridization and detected Eomes mRNA in cells transfected with pEomes-Cre and a Cre-conditional enhanced GFP (eGFP) reporter plasmid (Fig. 2, H and I). However, immunolabeling using an antibody against the EOMES protein failed to detect expression of EOMES in the eGFP-expressing aRGCs (Fig. 2, J to L). Thus, using morphological and gene expression tools, we revealed a pEomes-Cre+ apical precursor cell population that expresses Eomes mRNA but not the EOMES protein.

The detection of Eomes mRNA but not EOMES protein in certain mRGCs based on in silico and in vivo data, suggests that transcriptional priming, a phenomenon whereby mRNA for proteins that will be expressed in progeny is present but not translated in the parent cell (23), may contribute to key features of the developing mouse brain. To assess whether this phenomenon is widespread among progenitor cell populations in the developing mouse brain, we correlated mRNA and protein expression in several cell types and states exhibiting mixed character gene expression signatures similar to those we observed in mRGC2. To identify candidate genes/proteins potentially subject to transcriptional priming, we focused on the genes in the IPC module (M8) from the WGCNA analysis (Fig. 1F). Because genes from M8 are likely important for the establishment of IPC identity, it is reasonable that other genes from the module, in addition to Eomes, exhibit transcriptional priming in RGCs. We observed multiple M8 genes expressed in one or multiple states in RGCs (fig. S5G). In particular, Igsf8 was expressed by all states, except state IV, in mRGC2, whereas Mfap4 was only expressed by state III in mRGC2. Using immunohistochemistry, we found that IGSF8 and MFAP4 are widely expressed at the protein level in the mouse ventricular zone and are therefore not candidates for transcriptional priming (not shown). Applying this same approach to mIPC1, mIPC2, mIPC3, and mIPC5 also identified multiple states in each of these mIPC cell types characterized by expression of Eomes and many other genes previously attributed to bIPCs, although Eomes expression in these IPC groups was at least 10-fold greater than that found in mRGC2 (fig. S6).

Because the pEomes-Cre fate mapping approach labeled multiple morphotypes (Fig. 2D), we hypothesized that an in vivo approach restricting labeling to cells that coexpress both Eomes and apical marker genes such as Hes1, Fabp7, or Slc1a3 could specifically highlight the cells with mixed identity, including those within the mRGC2 and mIPC1 profiles. To this end, we designed an intersectional approach combining FLP recombinase (Flpe) driven by the Eomes promoter, an Flpe conditional plasmid expressing Cre under the control of one of the apical marker genes (e.g., Hes1, Slc1a3, or Fabp7), and a Cre-conditional eGFP reporter (Fig. 3A). Fifteen hours following IUE with these intersectional fate mapping plasmids at E14.5, most of the labeled cells resembled aRGCs and expressed SOX2 protein (Fig. 3, B and B2), demonstrating the presence of a subpopulation of aRGCs expressing the Eomes transcript as predicted by the expression profile of the mRGC2 cluster. In addition, a few cells with bRGC morphology were also present among the GFP-labeled cohort, and these bRGCs expressed EOMES protein (Fig. 3B1) as well as SOX2 (Fig. 3, D and E). By 24 hours elapsed time, the SOX2+/EOMES aRGCs in the VZ were joined by a much larger SOX2+/EOMES+ bRGC population in the subventricular zone (SVZ) (Fig. 3, C, C1, C2, and C3), consistent with the contemporaneous expression of aRGC and IPC genes (including Eomes) in mIPC1 (fig. S6A). Many of the cells with bRGC morphology were located adjacent to a second eGFP+ cell, suggestive of a recent cell division and the generation of a daughter cell within the 24-hour period Fig. 3 (D and E). Immunostaining for PH3 and SOX2 confirmed the proliferative status of eGFP+ bRGCs and indicated that they express SOX2 as in primate and carnivore brain (fig. S7A). The bRGCs as well as their daughter cells expressed the SOX2 protein (fig. S7, B and B), suggesting that they produce daughter cells that retain molecular aspects of apical progenitor identity despite their distinctive morphology and localization within deeper regions of the neocortical wall. Together, these results indicate that a subgroup of aRGCs expresses translationally blocked Eomes mRNA transcripts and that this lineage of aRGCs generates proliferative bRGCs.

(A) Intersectional (dual switch) genetic fate mapping strategy for in vivo labeling of cell types. The Flpe-conditional Cre construct used either Fapb7, or Slc1a3, or Hes1 promoters. (B) IUE to label cells coexpressing Eomes and Fabp7 at E14.5 with 15-hour survival. Proportion of each morphological cell type represented in pie chart. Eomes+ bRGCs (1) and Sox2+ aRGCs (2) were present. (C) IUE to label cells coexpressing Eomes and Fabp7 at E14.5 with 24-hour survival. Proportion of each morphological cell type represented in the pie chart. Transfectants include Eomes+ bRGCs (1 and 2) and Sox2+/Eomes aRGCs (3). (D) IUE to label cells coexpressing Eomes and Hes1 at E14.5 with 24-hour survival, demonstrating that bRGCs and their daughter cells express SOX2. (E) IUE to label cells coexpressing Eomes and Hes1 at E14.5 with 24-hour survival, demonstrating expression of SOX2 in aRGC and bRGC (white arrowheads) but not bIPCs (white arrows). (F to I) Pseudotime trajectories of mIPC1 (F), mIPC2 (G), mIPC3 (H), and mIPC5 (I). Color indicates pseudotime progression. Cell states are indicated with circled Roman numerals. Genes showing strong association with pseudotime and cell states are shown at the bottom of each panel. (J) Violin plot of canonical marker genes for RGCs and IPCs expressed by mIPCs. Colors represent different genes. Vertical axis shows normalized gene expression levels. Scale bars, 20 mm.

In addition to mIPC1, our bioinformatics analysis also revealed other IPC groups with mixed apical and basal gene expression (Fig. 3, F to I). Specifically, mIPC3 strongly expressed both Eomes and apical markers like Fabp7, but was further defined by the expression of NeuroD4 (Fig. 3J). A previous single-cell study bioinformatically identified a subset of cells that coexpress FABP7 and NEUROD4 as bRGCs in human and ferret neocortex, but a cognate population was absent in the mouse (24). To determine whether these NeuroD4+ mouse progenitors align with the bRGC morphotype, we fate mapped cells in the neocortical wall at E14.5 using pEomes and pNeuroD4 plasmids driving mRFP and GFP reporters, respectively (Fig. 4A). Cotransfection of these four constructs highlighted the overall Eomes-expressing cell population with RFP and identified that a subset of these cells (30%) also expressed NeuroD4 (GFP+). The NeuroD4+ subset was comprised entirely by cells with bIPC and bRGC morphology, the latter of which were often found closely opposed to a presumed daughter cell (Fig. 4, B and C, and fig. S7, C and D). Immunostaining showed that the NeuroD4 lineage bIPCs are EOMES+/SOX2, whereas the NeuroD4-expressing bRGCs are EOMES+/SOX2+ (Fig. 4D). To determine whether the NeuroD4+ bRGCs are the same population of bRGCs found in the Eomes/VZ gene intersectional cohort in Fig. 3, we quantified the proportion of pNeuroD4-creexpressing bRGCs in the total bRGC population. Using the dual-color StopLight reporter driven by the ubiquitous chicken beta-actin promoter, we identified the total bRGC population with morphological criteria and found that only 40% of the Eomes-expressing bRGCs also expressed NeuroD4 (Fig. 4, E to I). We then used fluorescence mRNA labeling along with intersectional fate mapping to confirm the presence of Eomes+/NeuroD4+ and Eomes+/NeuroD4 bRGCs in the mouse neocortical wall (fig. S7E to H). These are the first data to indicate multiple different classes of bRGCs in the mouse neocortex.

(A) Fate mapping constructs used to elucidate identity of cells expressing both Eomes and NeuroD4 via IUE in E14.5 mouse neocortex. (B) Quantification and morphologies of Eomes+/NeuroD4 and Eomes+/NeuroD4+ cells 24 hours after IUE. (C, B, B) Eomes+/NeuroD4+ cells exhibit bIPC and bRGC morphology. Cell colors as in (A). White arrows indicate radial processes, and yellow arrows indicate cell bodies. (D) NeuroD4-expressing cells in mouse neocortical wall 24 hours after IUE. Insets show numbered cells and their expression of Eomes and Sox2. White dashed lines show location of cell bodies. (E to G) NeuroD4 StopLight fate mapping with IUE on E14.5 followed by 24-hour survival demonstrates that NeuroD4+ bRGCs are Sox2+. White arrows indicate radial processes, and yellow arrows indicate cell bodies. (H and I) Quantification of bRGCs 24 hours after IUE with NeuroD4 fate mapping approach. NeuroD4+ bRGCs represent 38% of entire bRGC population. Scale bars, 50 mm.

Our published work demonstrates that neurons born from distinct precursor groups can express specific electrophysiological and morphological properties, even when they are generated on the same day and migrate to the same neocortical layer (14,15). We therefore sought to determine how the precursor diversity found in this single-cell study correlates with the multiple subgroups of excitatory neurons found after cell capture and analysis (e.g., mEx-1 through mEx-8). To do this, we focused on the mouse single-cell data and used novel trajectory reconstruction methods to resolve the pseudodevelopmental process from progenitors to highly differentiated excitatory neurons. Through this process, we were able to establish four well-separated streams emanating from the precursor cell types (fig. S8, A and B). The excitatory neurons in these streams expressed genes identifying them as either superficial (streams 1, 2, and 3) or deep (stream 4) excitatory neurons (fig. S8C). Stream 1 also displayed characteristics of immature neurons as shown by the expression of Neurod1. We then plotted the ExN groups onto these streams and found that mExN cell types exhibited highly specific locations within these streams (fig. S8D). Some mExN groups were primarily restricted to one stream (e.g., mExN1, mExN3, and mExN6), while other groups (mExN2, mExN4, and mExN7) were present in two streams, and cells from the mExN5 cluster were present in all four streams. These computational results support previous studies indicating that excitatory neuron identity is varied, as measured by gene expression profiling, and that excitatory neuron types potentially resolve into different lineage streams produced by neocortical precursors.

To determine whether specific precursor cell types may be lineally correlated with the streams and the ExN contained therein, we quantified the percentage of each precursor cell state (i.e., mRGC and mIPC cell types) in the four streams (fig. S8E). In general, multiple precursor types are found along any given stream trajectory, but the contributions of each precursor cell state to the streams are distinctive. For example, a majority of cells from state III in mRGC2 and mIPC4 contribute to stream 1, the stream that showed immature neuron characteristics. A high percentage of cells from mRGC1-II and mIPC5-III contribute significantly to stream 2 (superficial excitatory neurons). All states from mRGC1 and mIPC3 contribute predominantly to stream 3 (deep excitatory neuron). State I of mRGC2 as well as mIPC1 states I, II, and III contribute almost exclusively to stream 4 (superficial excitatory neurons). These analyses suggest that multiple different precursor types and states may underlie each stream of excitatory neurons and that particular admixtures of precursor cell types cooperate to produce specific lineage streams during neocortical neurogenesis. These data, coupled with our recent publications demonstrating that different precursor lineages produce ExN with specific properties (14, 15), suggest that the precursor heterogeneity identified in the current study, while subtle and dynamic, may be an important driving factor for excitatory neuron diversity and circuit complexity.

The morphology of bRGCs has been previously shown to be quite variable (25), and we noticed this as well. To quantify bRGC morphology, we conducted three-dimensional (3D) image analysis to determine whether bRGC shape differed between subtypes or across labeling procedures. We scored cells as belonging to one of three categories (fig. S8, F to H): type A, characterizing cells having many small filopodial projections along with short apical or basally directed main processes; type B, unipolar bRGCs with one relatively unbranched basally directed process that terminates before reaching the pia; and type C, unipolar bRGCs that project to the pial surface. We found that all dual switch labeling strategies yielded bRGCs with all three types of morphology, suggesting that these variations in shape may be a general property of bRGCs, perhaps relating to transitory phases of their maturation or proliferation state. We did find differences in proportions of bRGC type, though, suggesting that bRGC diversity may be correlated with signaling from the basal lamina and with cytoskeletal complexity during cell production. For example, the pEomes-Flpe + pFabp7-FNF-Cre population had a higher proportion of pia-touching type C bRGC, whereas the pEomes-Flpe + pSlc1a3-FNF-Cre population was overrepresented by short bRGCs of type A morphology (fig. S8, I to L). Together, these results confirmed the separation of cell types elucidated by the bioinformatics approaches and that Eomes-expressing bRGCs consist of multiple subgroups. We next sought to determine how similar these newly elucidated mouse cell types are to those found during human neocortical development, especially because primate bRGCs have not been previously described as part of the EOMES lineage.

To compare transcriptomic features of mouse and human neocortical stem and progenitor cells, we created a human cell database by combining multiple published human scRNA-seq datasets (2, 1618) of 12 to 20 postconceptional week (PCW) neocortex into one containing cell number comparable to our mouse dataset. We confirmed that the combined human data also contained all major cell types in the developing human neocortex (fig. S9, A to C) and then used several methods to conduct a cross-species comparison. First, we correlated the WGCNA modules identified from the mouse single-cell analysis to human single cells and found a similar correlation pattern, suggesting that core transcriptomic networks are shared by the same cell types across species (fig. S9D). This approach also identified a human IPC cell type with mixed character gene expression. Specifically, hIPC1 was highly correlated with both RGC (M1) and IPC (M8) modules (fig. S9D). Marker gene expression profiling confirmed the coexpression of RGC markers (i.e., SLC1A3, FABP7, and HES1) and IPC markers (i.e., EOMES) in hIPC1 (fig. S9E). Next, we used an established method (17) to integrate the human single-cell dataset with our mouse dataset and showed that all major cell types were well integrated between the two species (Fig. 5A and fig. S9, F to H). Focusing on RGCs and IPCs, we observed that certain human and mouse cell types overlap in UMAP (uniform manifold approximation and projection) space (Fig. 5, B and C). Using MetaNeighbor analysis (26), we identified pairs of human and mouse neural precursor cell types that were highly similar to each other after integration (Fig. 5D). DEX analysis was then performed separately for the human or mouse precursor types, and the intersection between the human and mouse results was used to identify common genes by cell type using stringent criteria (Materials and Methods; table S1). These genes were then used to conduct enrichment analysis for the shared human and mouse precursor cell types in the context of human developmental and neurodegenerative disorders (Fig. 5F). We found that some pairs of human and mouse cell types were enriched for genes associated with neurodevelopmental or neurodegenerative diseases. For example, genes specific to and shared by hIPC2 and mIPC3 were significantly enriched for low IQ and schizophrenia.

(A) UMAP plot of integrated human (4, 2224) and mouse datasets (open and gray circles, respectively). Colors represent different major cell types. (B and C) UMAP plots of integrated human (h) and mouse (m) RGC (B) and IPC (C) single-cell data. Human single cells are represented by circles, whereas mouse single cells by square. Colors represent cell types. (D) Heatmap plot of MetaNeighbor analysis. Colors represent AUROC score. (E) Enrichment analysis for genes associated with human neurodevelopmental and neurodegenerative disorders in human and mouse progenitor cell types. Clustering based on MetaNeighbor analysis is shown on top (colors represent clusters). Dashed line indicates clustering threshold. Heatmap color represents unadjusted P value. Significant enrichment at unadjusted P < 0.05 is indicated by box, and adjusted P value (Padj) < 0.05 by x. N.S., not significant. (F) Violin plot of common DEX genes in both human and mouse progenitors. Colors are the same as in (B), (C), and (E). Horizontal axis indicates scaled expression level (Scaled exp.).

In general, a continual transcriptomic profile shift emerged, with apical RGCs (i.e., mRGC1, hRGC2, and mRGC2) at one end and more differentiated IPCs (i.e., hIPC3, mIPC4, and mIPC5) at the other end, with combinations of canonical marker genes clearly demarcating the two ends of this range (Fig. 5F). Specifically, RGCs expressed HES1, ID4, CYR61, FOS, and TUBA1B at high levels consistently, whereas IPCs expressed EOMES, NEUROD1, ELAVL2, and ELAVL4. We observed similar mixed signatures in hRGC3, mIPC1, hIPC1, mIPC2, and hIPC2. For example, hRGC3, which is likely a human bRGC cell type based on HOPX expression (fig. S9E), also expressed IPC genes such as NEUROD6 and ELAVL4 at relatively high levels compared with other RGCs. Clusters mIPC1 and hIPC1, on the other hand, showed an undoubtable IPC identity with high levels of EOMES, but also expressed a panel of canonical RGC genes including ID4, FABP7, and CKB. We also observed that hIPC1 and hIPC3 expressed NEUROD4, perhaps highlighting a common bRGC precursor identity with mIPC3.

These gene expression results indicate that the human neocortex also contains multiple subtypes of bRGCs (i.e., expressing EOMES/NEUROD4 and EOMES/SOX2). To confirm this in vivo, we used multiplex fluorescence in situ hybridization to localize cells expressing NEUROD4, EOMES and SOX2 in sections of the human neocortex at 12 weeks of gestation. Because of fixation and RNA degradation artifacts in two of the three samples in our archive, we were only able to obtain results from one brain. Nevertheless, the mRNA localization we report for EOMES and SOX2 below matches the Allen Developing Human Brain Atlas and other previous publications. We found that EOMES and NEUROD4 are largely coexpressed in cells of the inner SVZ (iSVZ), although a substantial number of cells express only EOMES or NEUROD4 in this zone (Fig. 6, A to C). In contrast, the number of positively stained cells fell to 9.1% of the overall population in the outer SVZ (oSVZ) (Fig. 6, D and E). Whereas most of these labeled cells in the oSVZ expressed EOMES only (56%), 27.7% also expressed NEUROD4, while fewer cells (16.3%) expressed NEUROD4 alone (Fig. 6E). We noted that a substantial proportion (45.4%) of cells expressed NEUROD4 or EOMES mRNA in the human VZ as well (Fig. 6, F and G).

(A and B) Single-molecule multiplex mRNA hybridization (RNAScope) for NEUROD4 (green) and EOMES (red) in human 12wg neocortical wall. Boxed inset (B) shows larger magnification. Arrows indicate NEUROD4+/EOMES+ cells. (C) Quantification of EOMES+ (red), NEUROD4+ (green), and EOMES+/NEUROD4+ (blue) cells from the top of the ventricular zone (VZ) to the top of the OSVZ. (D and F) Quantification of all unlabeled (gray), EOMES+ (red), NEUROD4+ (green), and EOMES+/NEUROD4+ (blue) cells in OSVZ (D) and VZ (E). (E and G) Distribution of RNAScope+ cells expressing EOMES, NEUROD4, or both markers in OSVZ (E) and VZ (G); colors as in (C). (H and I) RNAScope for SOX2 (green) and EOMES (red) in human 12wg neocortical wall. Boxed inset (i) shows larger magnification. Arrows indicate SOX2+/EOMES+ cells. (J) Quantification of EOMES+ (red), SOX2+ (green), and EOMES+/SOX2+ (purple) cells from the top of the VZ to the top of the OSVZ. (K and M) Quantification of all unlabeled (gray), EOMES+ (red), SOX2+ (green), and EOMES+/SOX2 (purple) cells in OSVZ (K) and VZ (M). (L and N) Distribution of EOMES+, SOX2+, or EOMES+/SOX2+ cells in OSVZ (L) and VZ (N); colors as in (J).

Mapping of EOMES and SOX2 led to similar results. A significant number of iSVZ and oSVZ cells coexpressed EOMES and SOX2, and the SOX2+/EOMES+ population was greater in the iSVZ than in the oSVZ, where it comprised 9.6% of the labeled cells (Fig. 6, H to K). We also identified a large population of SOX2+/EOMES cells in the oSVZ that represented the largest population (73.1%) of labeled cells in this zone (Fig. 6L). As expected, the VZ contained a high number of SOX2+ cells and a very small number of EOMES-only cells. Unexpectedly, though, we found that 36% of the human VZ cells coexpressed SOX2 and EOMES, a finding that further supports the single-cell gene expression evidence for aRGC heterogeneity and identifying the presence of aRGC cell types with expression features, indicating transcriptional priming (Fig. 6, M and N). Together, these in vivo human data indicate substantial similarities with the mouse bRGC results, showing that NEUROD4/EOMES and SOX2/EOMES double-positive bRGCs exist in both species and that their parent cell types are present in the VZ. Furthermore, adding to this cell diversity, our RNA labeling studies indicate that the largest human oSVZ population is a SOX2-only population of oRG (Fig. 6, K and L) that has been previously identified (2729). This SOX2-only oRG cell type is not observed in the mouse neocortical SVZ.

Cellular imaging studies indicate that neocortical aRGCs can divide to generate neurons directly and can also produce other precursor types; how one group of cells accomplishes these varied tasks is unknown. Our bioinformatics and in vivo findings demonstrate a much larger variety of neural precursor cell types than previously recognized, indicating multiple types of specialized aRGCs and IPCs during neurogenesis. We showed that the dynamic transcriptomic states of specific aRGCs may be indicativeperhaps even instructiveto the route of differentiation that an individual RGC may undertake. In addition, in vivo validation experiments demonstrate that bRGC cells and their precursors share novel transcriptional profiles in the mouse and human neocortex, as well as species-specific profiles, that contribute to separate lineages in the developing brain. Here, we describe two subtypes of dorsal neocortical aRGCs in mouse and three aRGC subtypes in human. Two of these RGC types in each species (mRGC1, mRGC2, hRGC1, and hRGC2) exhibit remarkably shared properties, and one (hRGC3) is likely the SOX2-only bRGC precursor present in human but not mouse. We also identify three similar IPC subtypes in human and mouse as well as two mouse IPC types that do not appear to have human counterparts.

Crucially, the novel cellular diversity we describe is not represented exclusively by morphological or anatomical characteristics but rather by newfound mixed transcriptional profiles. Although previous scRNA-seq studies have categorized cell populations based on morphological type (i.e., aRGC versus bIPC versus bRGC) and the expression of cardinal transcription factor genes (24, 27), we found several clusters of cells that coexpressed gene sets previously regarded as exclusive for distinct progenitor populations. Moreover, our in vivo fate mapping and RNAScope analyses revealed that these mixed marker clusters are comprised by cells with multiple morphotypes, including subsets of aRGCs, bIPCs, and bRGCs. This suggests that transcriptional profiles may reflect discrete lineages of progenitors more accurately than morphological classes. It is noteworthy that the differences we found between states within any precursor cell type are subtle, both in terms of the number of DEX genes and the magnitude of differences in expression levels. Therefore, we suspect that the states are dynamic or cyclic in nature. However, the identification of developmental streams and the differential involvement of precursor cells, at the level of their cell states, suggest that the differences we observed may be instructive for neuronal differentiation and the establishment of neuronal diversity. While still preliminary, this observation sheds new light on the complexity of neuronal precursor populations and invites further investigation.

Transcriptional priming may underlie some aspects of the diversification of cell types and the complexity of precursor dynamics both within and between species. Regulatory mechanisms driving precursor diversity have long been known to include temporal maturation and epigenetic modification (23, 30, 31). Recently, transcriptional priming, or the accumulation of untranslated mRNAs preceding the staged expression of protein, has been linked to specification of neuronal subtypes of daughter cells (23). Here, we show that transcriptional priming of the transcription factor Eomes may be a driver of precursor and lineage diversity, consistent with another report describing changes in neuronal identity and localization in response to deletion of the Eomes gene (32). We observed, in particular, that subgroups of apical precursors within mouse and human VZ express Eomes mRNA but not protein. Fate mapping with the Eomes regulatory sequence supported this conclusion as we observed multiple precursor morphotypes, including aRGCs, which lacked immunoreactivity for the Eomes protein. This suggests that the Eomes transcript itself contains regulatory motifs that are not found in the mRNAs encoding our fluorescent reporters and that these properties allow for repression of Eomes translation in these precursors. miRNA-92b has been shown to bind to and regulate Eomes mRNA (33); its activity may be important in regulating apical-to-basal precursor transition within this lineage. Together, these results suggest that transcriptional profile diversity is seeded in the broader population of aRGC stem cells and is then further amplified by the progression of individual neuron-producing lineages. This may be comparable to, and potentially allows inferences to be drawn from, similar mechanisms underlying lineage diversification in the development of organ systems other than the brain (34).

While several studies have noted small numbers of cells in the mouse neocortex that resemble bRGCs (12, 13, 28, 35), they are thought to have lower proliferative capacity and unique gene expression profiles compared with those found in species with convoluted or gyrencephalic brains, such as ferret and human. These findings have prompted the theory that bRGCs have enabled the large expansion in cortical surface area during carnivore and primate evolution (11). However, here, we have identified and developed specific labeling tools for multiple mouse bRGCs as well as the aRGC group that precedes them. The presence of these subtypes of bRGCs in both the mouse and human neocortex provides a new facet to the theory that bRGC underlie gyrencephalization and cortical expansion. The bRGC subtypes we identified express similar gene and protein expression patterns in both species, clearly indicating their conservation during mammalian evolution. These cell types found in both human and mouse should be called bRGCs and not oRGs because the mouse neocortex does not contain an oSVZ and because most of these cells are found in the human iSVZ. However, our study also confirms the presence of a human-specific type of bRGC (SOX2-only, hRGC3) that is present in the oSVZ and has been previously named the oRG cell (11, 27). The presence of this oRG cell type in the human brain may lead to the expansion of the human neocortex.

The demonstration of multiple progenitor cell types and states supports a model whereby progenitor diversity yields neuronal diversity. In general, while a brain with more progenitor cells has a larger growth capacity, a brain with greater progenitor diversity may have important additional qualities. Formation of the neocortex by multiple groups of dividing progenitors provides a varied landscape from which individual neuron properties can be germinated; our scRNA-seq and in vivo fate mapping studies now confirm that such a varied landscape is present in both mouse and human neocortex. Our data indicate the existence of coherent molecular signatures that constitute a thread tying cells within the same lineage together, even though individual cells within the lineage express various levels of such threading genes along the path of differentiation and may be found in various morphological states. This lineage diversity is likely to be integral to cortical complexity. For example, several reports have indicated that the morphology and action potential firing properties of the eventually produced neurons can vary, even in the same cortical layer (i.e., neurons born at the same developmental time) (5, 36). These differences appear to correlate with the properties of the neurons parent cell type; we recently showed in mouse brain that progenitor lineage directly contributes to the intralaminar diversity of neurons both in the somatosensory and the frontal cortex (14, 15).

Overall, the bioinformatics results presented here identify unique expression profiles of progenitor diversity. These profiles then served as guides for in vivo fate mapping experiments that, in turn, reinforced and clarified the bioinformatics findings. The confirmed molecular properties can now be used to track the developmental roles of the multiple progenitor types undergoing neurogenesis in the fetal brain. Building information from fate maps of particular precursor lineages into a system-level analysis of neocortical circuitry and function will greatly elucidate how the neocortex is generated and how it is altered in neurodevelopmental disorders.

Cohorts of timed pregnant CD-1 IGS mice (#022) were obtained from Charles River at E9.5 or E10.5 stage and were maintained at the Boston University Laboratory Animal Science Center with a 12-hour light/dark cycle in conventional housing cages until surgery.

The ddSEQ Single-Cell Isolator (Bio-Rad and Illumina) was used for single-cell capture. Briefly, freshly dissected mouse brain tissue was transferred into a tube with 37C prewarmed trypsin solution. The mix was pipetted with a wide-bore pipette tip for 10 times, and then the tube was incubated in a 37C water bath for 30 min. The mix was gently pipetted 10 to 20 times every 10 min during incubation. After incubation, the cell suspension was repipetted again until homogenized. Last, the well-dissociated cell suspension was centrifuged at 300g for 3 min, washed, and resuspended in Dulbeccos phosphate-buffered saline (DPBS) to about 1000 cells/l. The cells were loaded onto the four wells of the ddSEQ Single-Cell Isolator following the manufacturers protocol to generate cDNA and sequencing libraries. The capture experiment was conducted in two separate technical replicates.

cDNA and sequencing library concentration was quantified with Quant-iT PicoGreen (Invitrogen, P7589). All sequencing libraries were assessed for quality by Agilent Bioanalyzer using high-sensitivity double stranded DNA (dsDNA) assay. Library was sequenced on an Illumina NextSeq 500 platform with the pair-end mode following the manufacturers instructions.

About 305 million (M) were generated, and FastQC was used to assess the quality of reads. Reads with average quality less than 30 were removed. We used SureCell RNA Single-Cell v1.1.0 (Illumina) to align all the reads in FastQC files to the mouse genome reference (mm10). Over 270M reads (89.58%) were aligned, with 260M that had valid barcode (85.6%). Among the aligned reads, 56.15% mapped to unique genes, whereas only 0.17% mapped to mitochondrial chromosome. We then assessed the distribution of unique molecular identifiers (UMI) in each cell as knee plot (fig. S1A) and removed barcodes with low UMI counts, with 16,681 barcodes remaining. We further removed low-quality barcodes with less than 200 total UMI counts, and 5777 cells passed quality control. UMI counts were normalized by NormalizeData function with log transformation using natural log as base.

The removal of CC effect was performed similarly as described before (20). Briefly, to minimize the effect of CC in the identification of progenitor cell types, we sought to remove CC from our data through regression. Briefly, we used a published list of CC genes (37) and calculated G1/S and G2/M phase scores for each cell using function CellCycleScoring from R package Seurat (38). Then, we calculated the difference between G1/S phase score and G2/M phase score. This result was used to perform regression on all cells in our dataset with Seurat. Using this approach, CC differences among dividing cells were regressed out, while signals segregating cycling and noncycling cells were maintained.

To define HVGs, we calculated the mean of logged expression values using Seurat function FindVariableGenes and plotted it against variance to mean expression level ratio (VMR) for each gene. Genes with log-transformed mean expression level between 1 and 8.5 and VMR above were considered as HVGs.

We used PCA and t-distributed SNE (19) as our main dimension reduction approaches. PCA was performed with RunPCA function (Seurat) using HVGs. Following PCA, we conducted JACKSTRAW analysis with 100 iterations to identify statistically significant (P < 0.01) PCs that were driving systematic variation. We used t-SNE to present data in 2D coordinates, generated by RunTSNE function in Seurat. Significant PCs identified by JACKSTRAW analysis were used as input. Perplexity was set to 30. t-SNE plots were generated using R package ggplot2 (39). Clustering was done with the Luvain-Jaccard algorithm using t-SNE coordinates by FindClusters function from Seurat with default setting.

WGCNA (20) was performed using R package WGCNA. The UMI counts from all cells were used to generate correlation matrix with bicorrelation algorithm. Next, pickSoftThreshold function was used to analyze the network topology with 3 as soft-threshold power. Minimum size of modules was set to 10 genes. Module was identified using the tree method with deepSplit. For each module, WGCNA generated an eigengene to represent modular features. Network edge and node information of each module were exported using exportNetworkToCytoscape function and was visualized with Cytoscape software.

The human authologs of the mouse genes from each module were selected. The expression of the selected genes was used in PCA, and the first PC was used as the module eigengenes.

We used R package Monocle3 alpha to reconstruct pseudotime on each of the analyzed progenitor cell type separately (40), following standard procedure with customized parameters. Briefly, we first calculated the dispersion of each gene and calculated an estimated dispersion by the mean-variance model using dispersionTable function. Only genes with dispersion greater than the estimated value and mean UMI greater than 0.1 were kept for further analysis. Then, preprocessing was conducted where the expression levels were log normalized with a residual model using number of UMI as the independent variable, followed by PCA (number of dimensions set to 30). UMAP was used to reduce dimensions further to two, with Minkowski metric. The number of neighbors was determined empirically based on the number of single cells in each cell type (ranging between 5 and 20). To identify states within each cell type, Louvain-Jaccard clustering was conducted. Ridge plots as in Figs. 2C and 3B were generated with ggridges package. Plot_pseudotime_heatmap function was used to visualize gene expression levels across pseudotime as in fig. S5 (C and D) and fig. S6 (A to D), with number of clusters set to 3 and a natural spline function with degree of freedom equal to 2.

The integration of human and mouse datasets was conducted following recommended steps (41). We used the top 2000 most variable features from each of the mouse and human single-cell datasets to find integration anchors. UMAP analysis was conducted with Minkowski metric. MetaNeighbor analysis was then conducted on the integrated data, using average expression levels of cell types from either species. Enrichment analysis for genes associated with human developmental and neurodegenerative disorders in human and mouse progenitor cell types was performed as previously described using genes specific to each human and mouse precursor cell type pairs (20). To identify genes specific to each pair of precursor cell types between human and mouse, we first conducted DEX analysis between cell types within same species to find genes specific to each human or mouse cell type. Then, we intersected the lists of DEX genes from mouse and human cell types of the same pair and regarded the intersected list as genes specific to the pair.

To identify neuronal differentiation lineages, we applied STREAM (v0.4.0) analysis pipeline (42) to a subset of our single-cell transcriptome dataset containing mRGCs, mIPCs, and mExNs. Briefly, the top 20 PCs from the selected cells were used to create a diffusion map with diffusion scale parameter of the Gaussian kernel (Sigma-Aldrich) set to 1 and number of nearest neighbors set to square root of the number of cells (43). The first three eigenvectors of the diffusion map were passed to STREAM pipeline, and differentiation lineages were identified by seed_elastic_principal_graph function (with number of initial nodes set to 10) followed by elastic_principal_graph function. To present the lineages, we used R package URD following recommended steps with minor adjustments based on the structure of the dataset (44). Briefly, mRGC1 was set as the root, and the diffusion map was flooded 1000 times to establish the pseudodevelopment axis. Tips of the diffusion map were identified from the final stage of pseudodevelopment. Biased random walks were then performed from each tip. Last, a tree graph was built using buildTree with cells per bin set to 25 and bins per window set to 8. A 2D representation of the resulted 3D graph from buildTree function was produced using R package rgl with a manually selected view point.

t-SNE plots were generated using TSNEPlot function from R package Seurat. Unless otherwise noted, all heatmaps were generated with R function heatmap.3. All other plots were generated using ggplot2.

IUE was performed as described previously (14) on E11.5, E13.5, and E14.5 timed pregnancies. Briefly, dams were anesthetized with ketamine/xylazine cocktail, and the uterine horns were exposed by a midline laparotomy. One to two microliters of plasmid, or plasmid combination, mixed with 0.1% fast green dye (Sigma-Aldrich) in phosphate buffer was injected into the lateral ventricles using a pulled glass micropipette and a picoinjector (PLI-100, Harvard Apparatus). Final plasmid or plasmid mixture concentration was between 3 and 6 g/l. The anode of a tweezertrode (1-mm diameter for E11.5, 3-mm diameter for E13.5, and 5 mm diameter for E14.5, Harvard Apparatus) was placed over the dorsal telencephalon above the uterine muscle, and four pulses (50 V for E11.5, 35 V for E13.5, and E14.5, 50-ms duration separated by 950-ms intervals) were applied with a BTX ECM830 square pulse generator (Harvard Apparatus). Following electroporation, the uterine horns were replaced into the abdomen, and the cavity was filled with warm 0.9% saline before suturing the abdominal muscle and skin separately. Dams were then placed into a clean cage for recovery and monitoring. These procedures were reviewed and approved by the Institutional Animal Care and Use Committee at Boston University School of Medicine.

For embryonic studies, the heads of electroporated embryos were harvested 24 hours after IUE, fixed overnight in 4% paraformaldehyde (PFA), and cryoprotected in 30% sucrose for 24 to 48 hours, or the brains were removed and cut into 60-m vibratome sections for morphometric analysis. Cryoprotected tissue was frozen in OCT compound in tissue molds with an ethanol/dry ice bath. Frozen tissue was cut into 20 m sections using an HM560 Cryostar cryostat and mounted and dried on to superfrost slides (Thermo Fisher Scientific). For all IUE studies, we used n = 4 brains. Before immunostaining, antigen retrieval was performed by microwaving sections in sodium citrate buffer [10 mM (pH 6)] at 800 W for 1 min followed by 80 W for 10 min. Sections were then blocked in diluent [5% goat serum, 0.3% Triton X-100, 1 phosphate-buffered saline (PBS)] for 1 hour at room temperature. Incubation with primary antibodies, anti-Sox2 (1:200; Santa Cruz), or anti-Tbr2 (1:250; Abcam), or anti-PH3 (1:300; Millipore) was performed overnight at 4C. Following three 5-min washes in PBS, sections were incubated for 2 hours at room temperature in diluent containing the appropriate secondary antibodies (1:250 for all). Sections were washed an additional three times for 5 min and mounted with Vectashield mounting medium containing 4,6-diamidino-2-phenylindole (DAPI). Then, 40 Z-stack images (15 m for cryosections, 20 m for vibratome sections) were acquired using an upright Zeiss LSM 710 microscope at a minimum of 1024 1024 resolution, and positive cells were identified and counted using LSM image browser software. Counts for each experiment were then averaged.

In situ hybridization for mRNA expression in the fixed-frozen mouse and human tissues was performed using RNAscope Multiplex Fluorescent Reagent Kit V2 (catalog no. 323100, Advanced Cell Diagnostics Inc., Hayward, CA) according to the manufacturers instructions. The commercially available human and mouse RNA probes were as follows: Hs-Eomes-C2 (429691-C2), Hs-Sox2 (400871), Mm-NeuroD4-O1-C2 (564191-C2), and Mm-Eomes-C2 (19078C), all from Advanced Cell Diagnostics Inc. The human probe Hs-NeuroD4-No-XMmRn (584701) was custom designed based on the NM_021191.3 cDNA sequence, targeting the region of 3180 to 3927 base pairs (bp) that does not overlap with other NeuroD genes.

Briefly, after pretreating of the section with hydrogen peroxide, followed by antigen retrieval (solution of 1 target retrieval, at 800 W for 1 min followed by 80 W for 10 min) and protease 3 pretreatment, the probes were incubated with the brain slices and the fluorescent dye for each detection channel was assigned as recommended. The signal was amplified using the multiplex reagents following the instructions.

The integrity of the RNA was confirmed in each tissue section using the RNAscope 3-plex Positive Control Probe for housekeeping gene expression (catalog no. 320861 for human tissue and catalog no. 320881 for mouse tissue). To confirm signal specificity, RNAscope 3-plex Negative Control Probe (catalog no. 320871 for human and mouse tissues) was used. After the final amplification, the slides were treated with Hoechst 33342 (catalog no. H3570, Invitrogen, Carlsbad, CA) for 10 min and sealed with coverslips using ProLong Gold Antifade Reagent (catalog no. P36930, Invitrogen, Carlsbad, CA).

Z-stack 20 images (16 m) were captured using a Zeiss LSM 710 microscope. Positive cells were identified and counted (four to five sections; N = 1 human brain) by two independent investigators using the LSM image browser software. The percentage of Eomes-, NeuroD4-, and Sox2-positive/double positive cells was assessed by normalizing the number to the total number of cells as marked by Hoechst nuclei staining. The laminar distribution analysis was performed using LSM image browser and Volocity software, and the results were plotted graphically using Sigma-Aldrich plot.

DEX analysis was conducted using Seurat function FindAllMarkers. Briefly, we took one group of cells and compared it with the rest of the cells using a Wilcoxon rank sum test. For any given comparison, we only considered genes that were expressed by at least 25% of cells in either population. Genes that exhibit Bonferroni-corrected P values under 0.01 were considered statistically significant.

To identify state-specific genes in mRGCs or mIPCs, we conducted principal graph test with nearest neighbor (k) parameter set to 10 (40). Genes expressed by more than 10% of cells in the state of interest and Morans I greater than 0.1 were considered as state specific. To generate gene expression heatmap over pseudotime, we used the plot_pseudotime_heatmap function from Monocle 3 Alpha with top 10 state-specific genes as input. A natural spline model was used to describe gene expression as a function of pseudotime, with degree of freedom set to 2.

Acknowledgments: We thank the Boston University Microarray and Sequencing Core Facility for help with the scRNA sequencing. Funding: This work was supported by the following PHS grants: R01 NS095654 (T.F.H. and N.S.), R21 NS089340 (T.F.H.), and P50 MH106934, RO1 MH110926, and UO1 MH116488 (N.S.). M.O. was supported by the Japan Society for the Promotion of Science (JSPS) Postdoctoral Fellowship for Research Abroad and the Kanae Foundation. G.S.B. was supported by the la Caixa Foundation (ID 100010434). Fellowship code was LCF/BQ/PI19/11690010. Author contributions: Z.L. contributed to the conceptualization, data curation, formal analysis, methodology, development of manuscript figures, writing of the original draft, and writing and editing of the manuscript. W.A.T. contributed to the conceptualization, data curation, formal analysis, methodology, development of manuscript figures, writing of the original draft, and writing and editing of the manuscript. E.Z. contributed to the data curation, formal analysis, development of manuscript figures, and editing of the manuscript. G.S.B. contributed to the formal analysis and data curation. M.O. contributed to the data curation, formal analysis, methodology, and development of manuscript figures and editing of the manuscript. T.G. and M.L. contributed to the formal analysis and data curation. N.S. contributed to the funding acquisition, project administration, supervision of Z.L., G.S.B., T.G., and M.L., and review and editing of the manuscript. T.F.H. contributed to the conceptualization, formal analysis, investigation, methodology, project administration, supervision of W.A.T., E.Z., and M.O., validation, visualization, writing of the original draft, and manuscript review and editing. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Sequences have been deposited to NCBI GEO GSE143949. Additional data related to this paper may be requested from the authors.

View post:
Transcriptional priming as a conserved mechanism of lineage diversification in the developing mouse and human neocortex - Science Advances

City of Hope Doctors Present New Research on Bone Marrow Transplants, Immunotherapy and Other Blood Cancer Treatments – Business Wire

DUARTE, Calif.--(BUSINESS WIRE)--City of Hope announced today that it will present data on new findings on bone marrow transplants, immunotherapies and other blood cancer treatments at ASH 62nd Annual Meeting and Exposition on Dec. 5 to 8, a virtual event.

City of Hope is addressing some of the hardest-to-treat cancers by accelerating innovative clinical research approaches. The comprehensive cancer center was a pioneer in bone marrow and stem cell transplants and the transplantation program is now one of the largest and most successful programs of its kind in the U.S. For the 15th year in a row, the Center for International Blood & Marrow Transplant Research has ranked City of Hope as providing exceptional care and strong clinical outcomes for patients who received bone or stem cell transplants; it is the only cancer center to hold this distinction.

During the ASH virtual conference, City of Hope researchers will make presentations on the following and other data:

Title: Efficacy of Post-Transplant Cyclophosphamide as Graft-Versus-Host Disease Prophylaxis After Peripheral Blood Stem Cell HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation; A Prospective Pilot Trial

Publication Number: 298

Type: Oral

Session Name: 732. Clinical Allogeneic Transplantation Results III

Session Date and Time: Saturday, Dec. 5, 2020, 2 to 3:30 p.m. ET

Presentation Time: 2:30 p.m.

Presenter: Monzr M. Al Malki, M.D., City of Hope Director of Unrelated Donor BMT Program and Haploidentical Transplant Program, Assistant Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation

Title: Consolidation With Nivolumab and Brentuximab Vedotin After Autologous Hematopoietic Cell Transplantation in Patients With High-Risk Hodgkin Lymphoma

Publication Number: 472

Type: Oral

Session Name: 624. Hodgkin Lymphoma and T/NK Cell LymphomaClinical Studies: Clinical Studies in Hodgkin Lymphoma Session Date and Time: Sunday, Dec. 6, 2020, 2 to 3:30 p.m. ET

Presentation Time: 2:30 p.m.

Presenter: Alex Herrera, M.D., City of Hope Assistant Professor, Department of Hematology & Hematopoietic Cell Transplantation

Title: Total Marrow and Lymphoid Irradiation (TMLI) at a Dose of 2000cGy in Combination With Post-Transplant Cyclophosphamide (PTCy)-Based Graft Versus Host Disease (GvHD) Prophylaxis Is Safe and Associated With Favorable GvHD-Free/Relapse-Free Survival at 1 Year in Patients With Acute Myeloid Leukemia (AML)

Publication Number: 192

Type: Oral

Session Name: 721. Clinical Allogeneic Transplantation: Conditioning Regimens, Engraftment and Acute Transplant Toxicities

Session Date and Time: Saturday, Dec. 5, 2020, Noon to 1:30 p.m. ET

Presentation Time: 12:45 p.m.

Presenter: Anthony S. Stein, M.D., City of Hope Associate Director, Gehr Family Center for Leukemia Research; Clinical Professor, Department of Hematology & Hematopoietic Cell Transplantation

Title: A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102

Publication Number: 75

Type: Oral

Session Name: 732. Clinical Allogeneic Transplantation: Results I

Session Date and Time: Saturday, Dec. 5, 2020, 7:30 to 9 a.m. ET

Presentation Time: 7:30 a.m.

Study Co-chair: Ryotaro Nakamura, M.D., City of Hope Director, Center for Stem Cell Transplantation; Professor, Department of Hematology & Hematopoietic Cell Transplantation

About City of Hope

City of Hope is an independent biomedical research and treatment center for cancer, diabetes and other life-threatening diseases. Founded in 1913, City of Hope is a leader in bone marrow transplantation and immunotherapy such as CAR T cell therapy. City of Hopes translational research and personalized treatment protocols advance care throughout the world. Human synthetic insulin and numerous breakthrough cancer drugs are based on technology developed at the institution. A National Cancer Institute-designated comprehensive cancer center and a founding member of the National Comprehensive Cancer Network, City of Hope has been ranked among the nations Best Hospitals in cancer by U.S. News & World Report for 14 consecutive years. Its main campus is located near Los Angeles, with additional locations throughout Southern California. For more information about City of Hope, follow us on Facebook, Twitter, YouTube or Instagram.

Original post:
City of Hope Doctors Present New Research on Bone Marrow Transplants, Immunotherapy and Other Blood Cancer Treatments - Business Wire